Redwoods Acquisition Files Proxy on $60M ANEW MEDICAL Deal

Redwoods Acquisition today filed a preliminary proxy and prospectus on its proposed merger with ANEW MEDICAL for $60 million in stock. Another $50 million in earnout shares would be issued if the company's srtock hits certain price milestones.

The target is an early-stage company focused on developing disruptive new therapies to treat neurodegenerative diseases. Omaha, NE-based ANEW currently lists on the OTC Markets under the symbol LEAS.

The transaction at deal announcement last May was expected to provide approximately $54 million of cash proceeds, which assumed no redemptions by Redwoods stockholders.

If approved, after closing ANEW MEDICAL expects to list on the .

Redwoods Acquisition is led by Jiande Chen, former CEO of IMAX China. Read more.


Source: Redwoods Acquisition Files Proxy on M ANEW MEDICAL Deal